

US010335584B2

(12) United States Patent

Hoang et al.

(54) PATIENT FLUID LINE ACCESS VALVE ANTIMICROBIAL CAP/CLEANER

- (71) Applicant: Becton, Dickinson and Company, Franklin Lakes, NJ (US)
- (72) Inventors: Minh Quang Hoang, Sandy, UT (US); Jonathan Karl Burkholz, Salt Lake City, UT (US)
- (73) Assignee: Becton, Dickinson and Company, Franklin Lakes, NJ (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 671 days.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: 15/041,939
- (22) Filed: Feb. 11, 2016

(65) **Prior Publication Data**

US 2016/0158521 A1 Jun. 9, 2016

Related U.S. Application Data

- (63) Continuation of application No. 14/159,959, filed on Jan. 21, 2014, now Pat. No. 9,283,367, which is a (Continued)
- (51) Int. Cl. *A61M 39/16* (2006.01) *A61M 39/02* (2006.01)

(Continued)

(10) Patent No.: US 10,335,584 B2

- (45) **Date of Patent:** *Jul. 2, 2019
- (58) Field of Classification Search CPC .. A61M 39/162; A61M 39/165; A61M 39/16; A61M 39/20

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,961,682 A 11/1960 Wurmböck et al. 3,047,139 A 7/1962 Jacoff (Continued)

FOREIGN PATENT DOCUMENTS

EP	1 649 890 A1	4/2006
EP	2 606 930 A1	6/2013
	(Conti	inued)

OTHER PUBLICATIONS

"Corrected Petition for Inter Partes Review Under 35 U.S.C. .sctn..sctn. 311-319 and 37 C.F.R. .sctn. 42,100 et seq.," USPTO, Patent Trial and Appeal Board, *Excelsior Medical Corporation* v. *Becton, Dickinson and Company*, Case IPR2014-00880, U.S. Pat. No. 8,740,864, pp. 1-48, Jun. 23, 2014.

(Continued)


Primary Examiner — Andrew M Gilbert

(74) Attorney, Agent, or Firm-Dickinson Wright, PLLC

(57) **ABSTRACT**

Cap and cleaning devices antiseptically maintain patient fluid line access valves to minimize the risk of infection via catheters. The devices have a cap that may contain a dry pad impregnated with an antimicrobial agent. The cap covers the access portion of the access valve when not in use. The devices have a hood that contains a wet pad impregnated with a cleaning solution and, optionally, an antimicrobial agent. The wet pad cleans the access portion of the access valve prior to and optionally, after the access valve is utilized to access the patient fluid line.

18 Claims, 7 Drawing Sheets



Related U.S. Application Data

continuation of application No. 11/281,711, filed on Nov. 17, 2005, now Pat. No. 8,740,864.

(51) Int. Cl.

A61M 39/20	(2006.01)
A61M 39/04	(2006.01)
A61M 39/10	(2006.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,136,416 A	6/1964	Goldrosen
3,147,876 A	9/1964	Lepore
4,280,632 A	7/1981	Yuhara
4,282,891 A	8/1981	Duceppe
4,354,490 A	10/1982	Rogers
4,417,890 A	11/1983	Dennehey et al.
4,432,764 A	2/1984	Lopez
4,440,207 A	* 4/1984	Genatempo A61L 31/16
	4/1004	150/154
4,444,310 A	4/1984	Odell
4,584,192 A	4/1986	Dell et al.
4,624,664 A	* 11/1986	Peluso A61M 39/165
A COC CCA A	12/1096	604/256
4,626,664 A	12/1986	Grise
4,655,762 A	4/1987	Rogers
4,671,306 A	6/1987	Spector Westfall at al
4,716,032 A	12/1987	Westfall et al. Virca
4,753,358 A	6/1988 * 10/1988	
4,778,447 A	* 10/1988	Velde A61M 39/10
4,915,934 A	4/1990	604/29 Tomlinson
4,913,934 A 4,925,668 A	5/1990	Khan et al.
4,989,733 A	2/1991	Patry
4,991,629 A	2/1991	Ernesto et al.
5,006,114 A	4/1991	Rogers et al.
5,023,082 A	6/1991	Friedman et al.
	* 3/1993	Kendell A61M 39/162
5,150,551 11	0,1000	604/29
5,195,957 A	3/1993	Tollini
5,197,620 A	3/1993	Gregory
	* 9/1993	White A61M 39/20
· · ·		604/256
5,334,388 A	8/1994	Hoang et al.
5,335,373 A	8/1994	Dangman et al.
5,512,199 A	4/1996	Khan et al.
5,547,662 A	8/1996	Khan et al.
5,554,106 A	9/1996	Layman-Spillar et al.
5,554,135 A	* 9/1996	Menyhay A61M 39/162
		138/89
5,569,207 A	10/1996	Gisselberg et al.
5,616,338 A	4/1997	Fox, Jr. et al.
5,620,424 A	4/1997	Abramson
5,639,310 A	6/1997	Giampaolo, Jr.
5,641,464 A	6/1997	Briggs, III et al.
5,686,096 A	11/1997	Khan et al.
5,694,978 A	12/1997	Heilmann et al.
5,702,017 A	12/1997	Goncalves
5,706,944 A	1/1998	Hoang et al.
5,722,537 A	3/1998	Sigler
5,743,884 A	4/1998	Hasson et al.
5,792,120 A	8/1998	Menyhay Usara at al
5,817,344 A	10/1998	Hoang et al.
5,861,440 A	1/1999	Gohla et al.
D410,081 S	5/1999	Sweeney et al.
5,954,957 A	9/1999	Chin-Loy et al.
5,989,229 A	11/1999 4/2000	Chiappetta Menubay
6,045,539 A	4/2000	Menyhay

6,051,609 A	4/2000	Yu et al.
6,074,366 A	6/2000	Rogers et al.
6,116,468 A	9/2000	Nilson
6,117,114 A *	9/2000	Paradis A61M 39/045
0,117,111 71	5/2000	604/246
6 146 260 1	11/2000	
6,146,360 A	11/2000	Rogers et al.
6,196,998 B1	3/2001	Jansen et al.
6,227,391 B1	5/2001	King
6,337,357 B1	1/2002	Fukunishi et al.
6,413,539 B1	7/2002	Shalaby
6,416,496 B1	7/2002	Rogers et al.
6,482,188 B1	11/2002	Rogers et al.
6,488,942 B1	12/2002	Ingemann
6,523,686 B1	2/2003	Bae
RE38,145 E	6/2003	Lynn
6,664,893 B1	12/2003	Eveland et al.
6,665,385 B2	12/2003	Rogers et al.
6,708,363 B2	3/2004	Larsen
6,846,846 B2*		
0,040,040 DZ	1/2005	
6 0 64 0 60 D 4		424/65
6,861,060 B1	3/2005	Luriya et al.
6,911,025 B2	6/2005	Miyahara
6,957,107 B2	10/2005	Rogers et al.
6,979,323 B2	12/2005	Rogers et al.
6,994,315 B2	2/2006	Ryan et al.
7,002,468 B2	2/2006	Eveland et al.
7,130,396 B2	2/2006	Rogers et al.
7,083,605 B2	8/2006	Miyahara
7,198,611 B2	4/2007	Connell et al.
7,198,800 B1	4/2007	Ko
	9/2007	Greten et al.
7,268,165 B2		
7,282,186 B2	10/2007	Lake, Jr. et al.
7,452,349 B2	11/2008	Miyahara
D607,325 S	1/2010	Rogers et al.
7,682,561 B2	3/2010	Davis et al.
7,704,002 B2	4/2010	Fisher et al.
7,704,935 B1	4/2010	Davis et al.
7,763,006 B2	7/2010	Tennican
7,780,794 B2	8/2010	Rogers et al.
7,828,186 B2	11/2010	Wales
7,857,793 B2	12/2010	Raulerson et al.
7,922,701 B2	4/2011	Buchman
7,985,302 B2	7/2011	Rogers et al.
	8/2011	Schweikert
7,993,309 B2		
8,065,773 B2 8,069,523 B2	11/2011	Vaillancourt et al.
- AU09.373 DZ	12/2011	Vaillancourt et al.
	0/0010	
8,113,731 B2	2/2012	Cable, Jr. et al.
8,113,731 B2 8,162,899 B2	4/2012	Tennican
8,113,731 B2 8,162,899 B2 8,167,847 B2	4/2012 5/2012	Tennican Anderson et al.
8,113,731 B2 8,162,899 B2	4/2012	Tennican
8,113,731 B2 8,162,899 B2 8,167,847 B2	4/2012 5/2012	Tennican Anderson et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2	4/2012 5/2012 5/2012	Tennican Anderson et al. Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2	4/2012 5/2012 5/2012 5/2012	Tennican Anderson et al. Solomon et al. Howlett et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2	4/2012 5/2012 5/2012 5/2012 6/2012	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012	Tennican Anderson et al. Solomon et al. Howlett et al. Rogers et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,273,303 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012 9/2012	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,273,303 B2 8,290,129 B2	4/2012 5/2012 5/2012 6/2012 6/2012 7/2012 9/2012 10/2012	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,273,303 B2 8,290,129 B2 8,328,767 B2	4/2012 5/2012 5/2012 6/2012 6/2012 6/2012 7/2012 9/2012 10/2012 12/2012	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,290,129 B2 8,328,767 B2 8,336,151 B2	4/2012 5/2012 5/2012 6/2012 6/2012 7/2012 9/2012 10/2012 12/2012	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al. Kerr et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,273,303 B2 8,290,129 B2 8,328,767 B2 8,336,151 B2 8,336,151 B2	4/2012 5/2012 5/2012 6/2012 6/2012 7/2012 9/2012 10/2012 12/2012 12/2012 12/2012	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al. Kerr et al. Vaillancourt et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,206,514 B2 8,206,514 B2 8,231,587 B2 8,273,303 B2 8,290,129 B2 8,328,767 B2 8,336,151 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2	4/2012 5/2012 5/2012 6/2012 6/2012 6/2012 7/2012 10/2012 12/2012 12/2012 12/2012 1/2013	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,233,303 B2 8,328,767 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,388,894 B2	4/2012 5/2012 5/2012 6/2012 6/2012 6/2012 7/2012 10/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,203,587 B2 8,273,303 B2 8,290,129 B2 8,328,767 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,348,894 B2 8,419,713 B1	4/2012 5/2012 5/2012 6/2012 6/2012 6/2012 7/2012 10/2012 12/2012 12/2012 12/2012 1/2013 3/2013 4/2013	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,206,514 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,231,587 B2 8,236,151 B2 8,336,151 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,388,894 B2 8,419,713 B1 8,491,546 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012 10/2012 12/2012 12/2012 12/2012 12/2013 3/2013 7/2013	Tennican Anderson et al. Solomon et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Hoang et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,290,129 B2 8,328,767 B2 8,336,151 B2 8,336,151 B2 8,343,112 B2 8,341,713 B1 8,491,546 B2 8,506,538 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013 4/2013 7/2013 8/2013	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Chelak
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,239,129 B2 8,328,767 B2 8,336,151 B2 8,336,151 B2 8,336,151 B2 8,343,112 B2 8,343,12 B2 8,343,13 B1 8,491,546 B2 8,506,538 B2 8,523,830 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012 9/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013 3/2013 8/2013 9/2013	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Solomon et al. Ferlic et al. Solomon et al. Ferlic et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,230,129 B2 8,328,767 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,343,112 B2 8,348,894 B2 8,419,713 B1 8,491,546 B2 8,523,830 B2 8,523,830 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012 1/2012 1/2012 1/2012 1/2013 3/2013 4/2013 8/2013 8/2013 9/2013	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Hoang et al. Chelak Solomon et al. Solomon et al. Solomon et al. Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,273,303 B2 8,290,129 B2 8,328,767 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,343,112 B2 8,348,894 B2 8,419,713 B1 8,491,546 B2 8,523,830 B2 8,523,831 B2 8,523,831 B2 8,628,501 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012 12/2012 12/2012 12/2012 12/2012 1/2013 3/2013 4/2013 7/2013 8/2013 9/2013 1/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al. Hoang et al. Hoang et al. Hoang et al. Hoang et al. Hoang et al. Hadden
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,231,587 B2 8,328,767 B2 8,336,151 B2 8,336,151 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,388,894 B2 8,419,713 B1 8,491,546 B2 8,506,538 B2 8,523,830 B2 8,523,831 B2 8,628,501 B2 8,641,681 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 10/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013 8/2013 9/2013 1/2014 2/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Hoang et al. Chelak Solomon et al. Solomon et al. Hoang et al. Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,230,129 B2 8,328,767 B2 8,336,151 B2 8,336,151 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,388,894 B2 8,419,713 B1 8,491,546 B2 8,506,538 B2 8,523,830 B2 8,523,831 B2 8,641,681 B2 8,647,308 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012 12/2012 12/2012 12/2012 12/2012 1/2013 3/2013 4/2013 7/2013 8/2013 9/2013 1/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al. Hoang et al. Hoang et al. Hoang et al. Hoang et al. Hoang et al. Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,231,587 B2 8,328,767 B2 8,336,151 B2 8,336,151 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,388,894 B2 8,419,713 B1 8,491,546 B2 8,506,538 B2 8,523,830 B2 8,523,831 B2 8,628,501 B2 8,641,681 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 10/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013 8/2013 9/2013 1/2014 2/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Hoang et al. Chelak Solomon et al. Solomon et al. Hoang et al. Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,230,129 B2 8,328,767 B2 8,336,151 B2 8,336,151 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,388,894 B2 8,419,713 B1 8,491,546 B2 8,506,538 B2 8,523,830 B2 8,523,831 B2 8,641,681 B2 8,647,308 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 10/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013 4/2013 9/2013 9/2013 1/2014 2/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al. Hadden Solomon et al. Solomon et al.
\$,113,731 B2 \$,162,899 B2 \$,167,847 B2 \$,172,825 B2 \$,177,761 B2 \$,197,749 B2 \$,206,514 B2 \$,231,587 B2 \$,231,587 B2 \$,231,587 B2 \$,230,129 B2 \$,328,767 B2 \$,336,151 B2 \$,336,151 B2 \$,336,151 B2 \$,336,151 B2 \$,336,151 B2 \$,334,112 B2 \$,343,112 B2 \$,343,112 B2 \$,343,112 B2 \$,343,112 B2 \$,343,112 B2 \$,343,112 B2 \$,344,19,746 B2 \$,506,538 B2 \$,523,830 B2 \$,523,830 B2 \$,523,831 B2 \$,641,681 B2 \$,647,308 B2 \$,647,326 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 10/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013 4/2013 8/2013 9/2013 9/2013 1/2014 2/2014 2/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Solomon et al. Vaillancourt et al. Solomon et al. Solomon et al. Colantonio et al. Solomon et al. Chelak Solomon et al. Solomon et al.
\$,113,731 B2 \$,162,899 B2 \$,167,847 B2 \$,172,825 B2 \$,177,761 B2 \$,197,749 B2 \$,206,514 B2 \$,231,587 B2 \$,230,129 B2 \$,328,767 B2 \$,336,151 B2 \$,336,152 B2 \$,343,112 B2 \$,364,513 B2 \$,523,830 B2 \$,523,831 B2 \$,523,831 B2 \$,628,501 B2 \$,641,681 B2 \$,647,308 B2 \$,647,326 B2 \$,696,820 B2	4/2012 5/2012 5/2012 6/2012 6/2012 7/2012 9/2012 12/2012 12/2012 12/2012 1/2013 3/2013 4/2013 9/2013 9/2013 1/2014 2/2014 2/2014 2/2014 4/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al. Solomon et al.
\$,113,731 B2 \$,162,899 B2 \$,167,847 B2 \$,172,825 B2 \$,177,761 B2 \$,197,749 B2 \$,206,514 B2 \$,206,514 B2 \$,231,587 B2 \$,230,129 B2 \$,328,767 B2 \$,336,151 B2 \$,336,152 B2 \$,343,112 B2 \$,336,152 B2 \$,343,112 B2 \$,348,894 B2 \$,348,894 B2 \$,419,713 B1 \$,491,546 B2 \$,523,830 B2 \$,523,831 B2 \$,628,501 B2 \$,647,308 B2 \$,647,308 B2 \$,647,326 B2 \$,671,496 B2 \$,696,820 B2 \$,721,627 B2	4/2012 5/2012 5/2012 6/2012 6/2012 6/2012 1/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013 8/2013 9/2013 1/2014 2/2014 2/2014 2/2014 3/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al. Solomon et al.
\$,113,731 B2 \$,162,899 B2 \$,167,847 B2 \$,172,825 B2 \$,177,761 B2 \$,197,749 B2 \$,206,514 B2 \$,231,587 B2 \$,230,129 B2 \$,328,767 B2 \$,336,151 B2 \$,336,152 B2 \$,343,112 B2 \$,364,513 B2 \$,523,830 B2 \$,523,831 B2 \$,523,831 B2 \$,628,501 B2 \$,641,681 B2 \$,647,308 B2 \$,647,326 B2 \$,696,820 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012 12/2012 12/2012 12/2012 12/2012 1/2013 3/2013 4/2013 9/2013 1/2014 2/2014 2/2014 2/2014 4/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al. Solomon et al. Allancourt et al. Vaillancourt et al. Vaillancourt et al. Alpert Hoang
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,232,767 B2 8,336,151 B2 8,336,151 B2 8,336,151 B2 8,336,151 B2 8,343,112 B2 8,348,894 B2 8,419,713 B1 8,491,546 B2 8,523,831 B2 8,628,501 B2 8,647,308 B2 8,648 B2 8,740,864 B2 8,740,	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 7/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013 4/2013 8/2013 9/2013 9/2013 1/2014 2/2014 2/2014 2/2014 2/2014 6/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Chelak Solomon et al. Chelak Solomon et al. Solomon et
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,172,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,230,129 B2 8,328,767 B2 8,336,151 B2 8,336,151 B2 8,336,151 B2 8,336,151 B2 8,343,112 B2 8,344,154 B2 8,506,538 B2 8,523,830 B2 8,523,831 B2 8,647,308 B2 8,740,864 B2 8,740,864 B2 8,777,504 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 12/2012 12/2012 12/2012 12/2012 12/2012 12/2012 12/2013 3/2013 4/2013 8/2013 9/2013 1/2014 2/2014 2/2014 2/2014 3/2014 5/2014 6/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Solomon et al. Ferlic et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Solomon et al. Chelak Solomon et al. Solomon et al.
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,236,151 B2 8,336,151 B2 8,336,152 B2 8,336,152 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,344,154 B2 8,506,538 B2 8,523,830 B2 8,523,830 B2 8,523,831 B2 8,647,308 B2 8,747,547 B2 8,789,713 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 1/2012 1/2012 1/2012 1/2012 1/2013 3/2013 4/2013 8/2013 9/2013 1/2014 2/2014 2/2014 2/2014 3/2014 6/2014 7/2014 7/2014 7/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Solomon et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al. Alpert Hoang
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,230,129 B2 8,328,767 B2 8,336,151 B2 8,336,152 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,364,52 B2 8,523,830 B2 8,523,831 B2 8,523,831 B2 8,628,501 B2 8,641,681 B2 8,647,308 B2 8,647,308 B2 8,647,308 B2 8,671,496 B2 8,671,496 B2 8,671,496 B2 8,671,496 B2 8,721,627 B2 8,740,864 B2* 8,777,504 B2 8,789,713 B2 8,808,637 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 1/2012 12/2012 12/2012 1/2013 3/2013 4/2013 7/2013 8/2013 9/2013 1/2014 2/2014 2/2014 3/2014 4/2014 5/2014 6/2014 7/2014 8/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Kerr et al. Vaillancourt et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al. Vaillancourt et al. Vaillancourt et al. Vaillancourt et al. Alpert Hoang
8,113,731 B2 8,162,899 B2 8,167,847 B2 8,177,825 B2 8,177,761 B2 8,197,749 B2 8,206,514 B2 8,231,587 B2 8,231,587 B2 8,236,151 B2 8,336,151 B2 8,336,152 B2 8,336,152 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,343,112 B2 8,344,154 B2 8,506,538 B2 8,523,830 B2 8,523,830 B2 8,523,831 B2 8,647,308 B2 8,747,547 B2 8,789,713 B2	4/2012 5/2012 5/2012 5/2012 6/2012 6/2012 1/2012 1/2012 1/2012 1/2012 1/2013 3/2013 4/2013 8/2013 9/2013 1/2014 2/2014 2/2014 2/2014 3/2014 6/2014 7/2014 7/2014 7/2014	Tennican Anderson et al. Solomon et al. Howlett et al. Howlett et al. Rogers et al. Solomon et al. Ferlic et al. Rogers et al. Solomon et al. Solomon et al. Solomon et al. Colantonio et al. Solomon et al. Hoang et al. Chelak Solomon et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al. Solomon et al. Alpert Hoang

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,832,894 B2	9/2014	Rogers et al.
8,834,650 B2	9/2014	Rogers et al.
8,845,593 B2	9/2014	Anderson et al.
8,961,475 B2	2/2015	Solomon et al.
8,968,268 B2	3/2015	Anderson et al.
8,999,073 B2	4/2015	Rogers et al.
9,039,989 B2	5/2015	Liu et al.
9,101,750 B2	8/2015	Solomon et al.
9,259,535 B2	2/2016	Anderson et al.
9,283,367 B2	* 3/2016	Hoang A61M 39/02
9,283,368 B2	3/2016	Hoang et al.
9,283,369 B2	3/2016	Ma et al.
9,399,125 B2	7/2016	Burkholz
9,480,833 B2	11/2016	Hoang et al.
2001/0016589 A1	8/2001	Modak et al.
2002/0144705 A1	10/2002	Brattesani et al.
2002/0193752 A1	12/2002	Lynn
2003/0040708 A1	2/2003	Rogers et al.
2003/0072781 A1	4/2003	Pelerin
2003/0109853 A1	* 6/2003	Harding A61M 39/045
		604/536
2003/0153865 A1	8/2003	Connell et al.
2003/0162839 A1	8/2003	Symington et al.
2004/0004019 A1	* 1/2004	Busch A61B 17/3401
		206/571
2004/0039349 A1	2/2004	Modak et al.
2004/0073171 A1	4/2004	Rogers et al.
2004/0258560 A1	* 12/2004	Lake, Jr A61L 2/18
		422/28
2005/0124970 A1	6/2005	Kunin et al.
2005/0147524 A1	7/2005	Bousquet
2005/0147525 A1	7/2005	Bousquet
2005/0165351 A1	7/2005	Tamagni, Jr.
2005/0222542 A1	10/2005	Burkholz et al.
2006/0030827 A1	2/2006	Raulerson et al.
2006/0165751 A1	7/2006	Chudzik et al.
2006/0239954 A1	10/2006	Sancho
2007/0112333 A1	5/2007	Hoang et al.
2007/0202177 A1	8/2007	Hoang
2007/0225660 A1	9/2007	Lynn
2007/0282280 A1	12/2007	Tennican
2008/0019889 A1	1/2008	Rogers et al.
2008/0027399 A1	1/2008	Harding et al.
2008/0033371 A1	2/2008	Updegraff et al.
2008/0075761 A1	3/2008	Modak et al.
2008/0086091 A1 2008/0095680 A1	4/2008	Anderson et al. Steffens et al.
	4/2008 6/2008	Davis et al.
2008/0147047 A1 2008/0177250 A1	7/2008	Howlett et al.
2008/01/7230 AI 2008/0182921 AI	7/2008	Suh et al.
2008/0283534 A1	11/2008	Paz
2008/0285554 AI 2009/0008393 AI	1/2008	Howlett et al.
2009/0028750 A1	1/2009	Ryan
2009/0028756 A1	1/2009	Shahriari
2009/0062766 A1	3/2009	Howlett et al.
2009/0149818 A1	6/2009	Timm
2009/0149819 A1	6/2009	Chelak
2009/0175759 A1	7/2009	Davis et al.
2010/0000040 A1	1/2010	Shaw et al.
2010/0047123 A1	2/2010	Solomon et al.
2010/0049170 A1	2/2010	Solomon et al.
2010/0050351 A1	3/2010	Colantonio et al.
2010/0172794 A1	7/2010	Ferlic et al.
2010/0204648 A1	8/2010	Stout et al.
2010/0292673 A1	11/2010	Korogi et al.
2010/0306938 A1	12/2010	Rogers et al.
2011/0150958 A1	6/2011	Davis et al.
2011/0232020 A1	9/2011	Rogers et al.
2011/0265825 A1	11/2011	Rogers et al.
2011/0290799 A1	12/2011	Anderson et al.
2011/0314619 A1	12/2011	Schweikert

2012/0016318 A1	1/2012	Hoang et al.
2012/0039765 A1	2/2012	Solomon et al.
2012/0078203 A1	3/2012	Gaube et al.
2012/0216359 A1	8/2012	Rogers et al.
2012/0216360 A1	8/2012	Rogers et al.
2012/0283693 A1	11/2012	Anderson et al.
2012/0315201 A1	12/2012	Ferlic et al.
2013/0030414 A1	1/2013	Gardner et al.
2013/0072909 A1	3/2013	Solomon et al.
2013/0136801 A1	5/2013	Tennican
2013/0138083 A1	5/2013	Tennican
2013/0138085 A1	5/2013	Tennican
2013/0171030 A1	7/2013	Ferlic et al.
2013/0199947 A1	8/2013	Tennican
2013/0270270 A1	10/2013	Reinders
2013/0335195 A1	12/2013	Rogers
2013/0345645 A1	12/2013	Chelak
2014/0135739 A1	5/2014	Solomon et al.
2014/0150832 A1	6/2014	Rogers et al.
2014/0182623 A1	7/2014	Vaillancourt et al.
2014/0188089 A1	7/2014	Midgette et al.
2014/0248181 A1	9/2014	Solomon et al.
2014/0248182 A1	9/2014	Solomon et al.
2014/0261558 A1	9/2014	Rogers et al.
2014/0261581 A1	9/2014	Rogers
2014/0366914 A1	12/2014	Kerr et al.
2015/0018774 A1	1/2015	Anderson et al.
2015/0086441 A1	3/2015	She et al.
2015/0094694 A1	4/2015	Stone et al.
2015/0217106 A1	8/2015	Banik et al.
2015/0273199 A1	10/2015	Adams et al.
2015/0314119 A1	11/2015	Anderson et al.
2015/0314120 A1	11/2015	Gardner
2016/0015959 A1	1/2016	Solomon et al.
2016/0074648 A1	3/2016	Kerr et al.
2016/0325089 A1	11/2016	Burkholz

FOREIGN PATENT DOCUMENTS

JP	S58-501359 A	8/1983
JP	2001-258713 A	9/2001
JP	2009-511181 A	3/2009
JP	2010-516342 A	5/2010
JP	5867703 B2	2/2016
WO	87/00441 A1	1/1987
WO	99/29173 A1	6/1999
WO	2006/019782 A2	2/2006
WO	2007/044760 A2	4/2007
WO	2007/137056 A2	11/2007
WO	2008/100950 A2	8/2008
WO	2008/157092 A1	12/2008
WO	2010/039171 A1	4/2010
WO	2010/143693 A1	12/2010
WO	WO-2010141508 A1	12/2010
WO	2011/053924 A1	5/2011
WO	2011/066586 A1	6/2011
WO	2015044904 A1	4/2015

OTHER PUBLICATIONS

"Decision, Institution of Inter Partes Review, 37 C.F.R. .sctn. 42,108," USPTO, Patent Trial and Appeal Board, *Excelsior Vledical Corporation* v. *Becton, Dickinson and Company*, Case IPR2014-00880, U.S. Pat. No. 8,740,864, pp. 1-21, Nov. 25, 2014.

"Patent Owner's Preliminary Response Under 37 C.F.R. .sctn. 42,10," USPTO, Patent Trial and Appeal Board, *Excelsior Vledical Corporation v. Becton, Dickinson and Company,* Case IPR2014-00880, U.S. Pat. No. 8,740,864, pp. 1-30, Sep. 16, 2014. 3M Health Care, "M Cures, let Dicipication Care, "YouTuba

3M Health Care, "3M Curos Jet Disinfecting Cap Video," YouTube, Nov. 21, 2016, 1:12, 1:21-1:34. www.youtube.com/watch?v= MiUNz7lmuK4.

* cited by examiner






FIG. 1





BAXTER EXHIBIT 1001 Page 5 of 14

FIG. 4







FIG. 5







BAXTER EXHIBIT 1001 Page 8 of 14




FIG. 9




FIG. 10A





FIG. 10B



BAXTER EXHIBIT 1001 Page 10 of 14 10

15

PATIENT FLUID LINE ACCESS VALVE ANTIMICROBIAL CAP/CLEANER

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/159,959, filed Jan. 21, 2014, titled PATIENT FLUID LINE ACCESS VALVE ANTIMICROBIAL CAP/ CLEANER, now U.S. Pat. No. 9,283,368, which is a continuation of U.S. application Ser. No. 11/281,711, filed Nov. 17, 2005, titled PATIENT FLUID LINE ACCESS VALVE ANTIMICROBIAL CAP/CLEANER, now U.S. Pat. No. 8,740,864, which are incorporated herein in their entirety.

BACKGROUND OF THE INVENTION

Catheter-related bloodstream infections are caused by bacteria/fungi in patients with intravascular catheters. These infections are an important cause of illness and excess medical costs, as approximately 80,000 catheter-related bloodstream infections occur in U.S. intensive care units each year. In addition to the monetary costs, these infections are associated with anywhere from 2,400 to 20,000 deaths per year.

Guidelines from the Centers for Disease Control and Prevention describe various ways to limit catheter-related bloodstream infections in hospital, outpatient and home care settings. The guidelines address issues such as hand hygiene, catheter site care and admixture preparation. Despite these ³⁰ guidelines, 15 catheter-related bloodstream infections continue to plague our healthcare system.

Impregnating catheters with various antimicrobial agents is one approach that has been implemented to prevent these infections. These catheters, however, have given less than ³⁵ satisfactory results. In addition, some microbes have developed resistance to the various antimicrobial agents in the system.

In another system that is commercially available in Europe, a catheter hub containing an antiseptic chamber is ⁴⁰ filled with three percent iodinated alcohol. Though it has shown to be effective, the catheter hub is expensive and does not fare as well in a formal cost-benefit analysis. Therefore, there is a need for an effective and inexpensive way to reduce the number of catheter-related infections. ⁴⁵

BRIEF SUMMARY OF THE INVENTION

The present invention is a device for antiseptically maintaining a patient fluid line access valve. The device includes ⁵⁰ a housing for covering the access portion of the access valve. A pad within the housing contacts the surface of the access portion of the access valve prior to (and optionally after) accessing the patient fluid line via the access valve to reduce the amount of microbes on the valve's access portion. ⁵⁵

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an exploded view of a first representative embodiment of a cap/cleaner device and a patient fluid line 60 access valve.

FIG. **2** is a cross-sectional side view of the first representative embodiment of the cap/cleaner device.

FIG. **3** is a cross-sectional side view of the first cap/ cleaner device capping a patient fluid line access valve. 65

FIG. **4** is a cross-sectional side view of the first cap/ cleaner device cleaning a patient fluid line access valve.

FIG. **5** is a flow chart illustrating representative embodiments of methods of using the cap/cleaner device.

FIG. **6** is a perspective view of a second representative embodiment of a cap/cleaner device.

- FIG. 7 is a cross-sectional side view of the second cap/cleaner device.
- FIG. 8 is a cross-sectional view of a first separable connector.
 - FIG. 9 is a side view of a second separable connector.
 - FIG. **10**A is a cross-sectional view of cleaning device.
 - FIG. 10B is a cross-sectional view of a capping device.

DETAILED DESCRIPTION

FIG. 1 shows an exploded view of patient fluid line access valve cap/cleaner device 10 with patient fluid line access valve A and patient fluid line B. Cap/cleaner 10 includes housing 12 with cap end 14, cleaning end 16 and thread 18; and lid 20. Access valve A includes housing A2 with thread A4 and septum A6 with slit A8. The exposed surface of septum A6 along with at least a portion of the exposed surface of housing A2 that surrounds septum A6, form access portion A10 of access valve A. Line B may be any of a number of types that include, for example, intravascular (IV) lines and catheters, saline wells, arterial lines and hemodialysis lines.

As will be described in more detail below, cap end 14 of cap/cleaner 10 attaches to access portion A10 of access valve A. Housing 12 is made from any of a number of types of plastic materials such as polycarbonate, polypropylene, polyethylene, glycol-modified polyethylene terephthalate, acrylonitrile butadiene styrene or any other moldable plastic material used in medical devices.

Cap end 14 of housing 12 is open and contains thread 18 along the inside of the opening. Cleaning end 16 is covered by lid 20. Lid 20 is typically made of foil or similar type material and completely seals the opening (not shown) of cleaning end 16. Any type of material or seal may be used as long as a moisture barrier is provided.

FIG. 2 shows cap/cleaner 10 in more detail. In addition to the structures shown in FIG. 1, cap/cleaner 10 also includes internal wall 12a, hood 16a and chamber 16b of cleaning end 16, cap 14a and cavity 14b of cap end 14, wet pad 22 within chamber 16b and dry pad 24 within cavity 14b. Internal wall 12a separates cap end 14 and cleaning end 16.

Cap/cleaner 10 is typically distributed and stored in a sterile, sealed package either alone or paired with a patient fluid line access valve. One such type of valve is the BD Q-SyteTM valve from Becton, Dickinson and Company (illustrated in FIG. 1). However, cap/cleaner 10 is useful with any type of needleless or needle required access valve. Once removed from the package, cap/cleaner 10 is ready for use.

FIG. 3 illustrates cap/cleaner 10 covering access portion
55 A10 of access valve A. Septum A6 provides an accessible seal for either a needle or a male luer taper. In the case of a needleless access device, such as that shown in FIG. 3, slit A8 extends through septum A6 to provide a port for insertion of the male luer taper.

As shown, cap end 14 includes cap 14a with cavity 14b, which contains dry pad 24. Dry pad 24 is impregnated with an antimicrobial agent to aid in maintaining antiseptic conditions of access portion A10 of valve A. Suitable material for dry pad 24 includes non-woven material or a foam sponge pad made of polyurethane, polyester, cotton or any bioengineered plastic material such as silicone. Any of a number of antimicrobial agents may be used to impregnate

45

dry pad **24**. Some examples include chlorhexidine gluconate, chlorhexidine diacetate, chloroxylenol, povidone iodine, Triclosan, benzethonium chloride, benzalkonium chloride, octenidine, antibiotic, etc. Alternatively, cap end **14** does not contain dry pad **24** and aids in maintaining antiseptic conditions by simply covering access portion A**10**.

In use, cap end 14 of cap/cleaner 10 is placed over access portion A10 such that access portion A10 is within cavity 14b of cap end 14. Cap/cleaner 10 may be attached either prior to or after placement of valve A for the patient. As 10 shown in FIG. 3, valve A includes thread A4. By rotating cap/cleaner 10 or valve A relative to one another, threads A4 and 18 (of cap/cleaner 10) interlock to provide a secured attachment. It is not necessary, however, for valve A to include thread A4. Cap end 14 will also attach and hold a 15 luer slip, which does not have a thread. In other embodiments, cap/cleaner 10 may be manufactured without a thread.

The amount of material used for dry pad 24 can vary. Typically, there is enough material for dry pad 24 to contact ²⁰ at least septum A6 of valve A. Enough space should be left in cavity 14b of cap end 14 for access portion A10 of valve A to be encompassed by cap end 14, thus, maintaining antiseptic conditions of the surface. By maintaining antiseptic conditions of the surface, the risk of microbes penetrating ²⁵ into valve A is minimized.

To further minimize the opportunity for penetration by microbes, access portion A10 is cleaned prior to accessing valve A with a needle or male luer taper. FIG. 4 illustrates cap/cleaner 10 cleaning access portion A10 of valve A.

As shown in FIG. 4, cleaning end 16 includes hood 16*a* and chamber 16*b*, which contains wet pad 22. Wet pad 22 is impregnated with a cleaning agent and optionally, an antimicrobial agent. Wet pad 22 may be made from materials similar to those described for dry pad 24.

The cleaning solution is typically an alcohol- or waterbased solution. A suitable alcohol-based solution contains about 50% to about 100% (no additional water) of an alcohol solution. The balance of solutions that are less than 100% alcohol contain water and other optional materials such as 40 fragrance, dye, surfactant, emollient, etc.

Suitable water-based solutions contain about 1% to about 10% alcohol solvent as a wetting agent and about 90% to about 99% water. Again, optional materials may also be added such fragrance, dye, surfactant, emollient, etc.

In an alternative embodiment, the cleaning solution also includes an antimicrobial agent. Any of a number of antimicrobial agents may be used in wet pad **22**. Some examples include chlorhexidine gluconate, chlorhexidine diacetate, chloroxylenol, povidone iodine, Triclosan, benzethonium ⁵⁰ chloride, benzalkonium chloride, octenidine, antibiotic, etc. Wet pad **22** and dry pad **24** may be impregnated with the same or different antimicrobial agents.

As shown in the Figures, cleaning end **16** is larger than cap end **14**. The hood of cleaning end **16** loosely encom-55 passes at least access portion A**10** of valve A, and chamber **16***b* is sized to allow some movement when access portion A**10** is inserted. The amount of material used for wet pad **22** will vary, but the amount should hold enough cleaning solution and allow enough movement for thorough cleaning. 60 Wet pad **22** should be contained entirely within hood **16***a* such that it is recessed inside chamber **16***b* of cleaning end **16**.

In preparation for accessing valve A, cap end **14** is removed from valve A either by rotating cap/cleaner **10** to 65 release threads **18** and A**4** or by simply pulling if valve A does not have a thread. Lid **20** is removed from cleaning end 4

16. Cleaning end 16 is then placed over at least access portion A10, such that wet pad 22 contacts septum A6. Though FIG. 4 only shows contact with septum A6, additional pressure may be applied such that wet pad 22 extends beyond the edges of septum A6 to contact portions of the exposed surface of housing A2.

Next, for thorough cleaning, wet pad **22** should scrub access portion A**10** of valve A. Scrubbing may be accomplished by, for example, rotational movement or back and forth movement. Scrubbing should be carried out for a time long enough to allow the cleaning solution to at least disinfect access portion A**10** of valve A.

Once cleaned, valve A is ready to use. A needle or male luer taper is inserted to either infuse or withdraw fluid from the patient fluid line.

FIG. 5 is a flowchart illustrating representative embodiments of methods for using cap/cleaner 10. Capping step 34, cleaning step 36 and accessing step 38 were described above and are the same in each embodiment. However, upon withdrawal after accessing the patient fluid line, access portion A10 of valve A may either be immediately capped or cleaned again prior to capping. If immediately capped, a new, second cap/cleaner 10A is obtained and removed from its package. This is represented by step 40. Cap end 14 of cap/cleaner 10A is placed over access portion A10 as described above. Cleaning end 16 of cap/cleaner 10A is sealed and ready for the next time valve A is utilized.

Alternatively, access portion A10 may be cleaned again prior to capping. This can be performed in one of the following ways. First, in step 42, cleaning end 16 of cap/ cleaner 10 is reused to clean access portion A10, which is then capped, at step 44, with cap end 14 of a new, second cap/cleaner 10A. Second, in step 46, cleaning end 16 of a new, second cap/cleaner 10A is used to clean access portion A10. Then, valve A maybe capped either with cap end 14 of cap/cleaner 10A (step 48) or of a new, third cap/cleaner 10B (step 50). Third, in step 52, access portion A10 may be cleaned with an alternative disposable cleaning devices that is well known in the art. Examples of such cleaning devices include alcohol wipes, iodine swabs, etc. Once cleaned, cap end 14 of a new, second cap/cleaner 10A may be attached to valve 26 (step 50).

Additional embodiments of the present invention include separable and individual, uncoupled devices. FIG. 6 shows separable cap/cleaner 56. Separable cap/cleaner 56 includes cap end 58, cleaning end 60 and gap 62. Gap 62 is the separation between cap end 58 and cleaning end 60.

FIG. 7 shows separable cap/cleaner 56 in more detail and further includes dry pad 64 within cap end 58, wet pad 66 within cleaning end 60 and breakable connector 68. In use, separable cap/cleaner 56 operates as described above for 10 cap/cleaner 10 except that cleaning end 60 may be removed after cleaning access portion A10 of valve A. Detaching cleaner 56 by only maintaining cap end 58 over access portion A10.

FIG. 8 shows a representative embodiment of breakable connector 68. Connector 68 is typically made of the same material from which housing 12 is fabricated. Torsional shearing caused by twisting cap end 58 and/or cleaning end 60 relative to each other may be used to break connector. Alternatively, a three-point bending force, which consists of a fulcrum (connector 68) that directs a force vector contralateral to the direction of the terminal (cap end 58 and cleaning end 60) force vectors, may be applied for breaking connector 68. Once removed, cleaning end 60 may be discarded.

FIG. 9 is an alternate embodiment showing notched breakable connector 70. Notch 72 within connector 70 is an area of reduced cross-sectional area, which acts as a score to facilitate breaking of connector 70.

Other separation mechanisms may also be used to remove 5 cleaning end 60 from cap end 58. For instance, a luer lock type mechanism can be utilized to separate ends 58 and 60 from each other.

FIG. 10A shows a representative embodiment of cleaning device 74 with lid 74a and wet pad 76. Here, cleaning device 10 74 is a stand-alone device that is used as described above for cleaning end 16.

FIG. 10B shows a representative embodiment of cap device 78 with lid 78a and pad 80. Cap device 78 is a stand-alone device where pad 80 may either be a wet pad or 15 a polyethylene or polypropylene material. a dry pad. Where pad 80 is a dry pad, cap device 78 is used as described above for cap end 14.

Where pad 80 is a wet pad, cap device 78 may be used to clean access portion A10 of valve A in addition to its capping function. The twisting motion involved in removing and 20 a dry pad. placing cap device 78 with respect to access potion A10 provides friction for cleaning. Additional cleaning can be accomplished by twisting cap device 78 in one direction and then in the reverse direction for a desired amount of time.

Cap device 78 further comprises an inner circumference 25 82 that defines a cavity in which pad 80 is housed. In some instances, cap device 78 comprises a thread or threading 18 having a length that is less than inner circumference 82.

With either cleaning device 74 or cap device 78, additional gripping surface may be added by extending the 30 length of the housing. The increased gripping surface would provide easier handling of devices 74 and 78.

Cap/cleaner 10 cleans and maintains access valves in antiseptic or aseptic condition. This substantially decreases the risk of patient infections caused by the ingress of 35 microbes into the access valves, particularly for needleless access valves.

Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and 40 detail without departing from the spirit and scope of the invention.

The invention claimed is:

1. A device for maintaining a patient fluid line access valve having an access portion with a distalmost end face 45 that includes a septum and external threads on the access portion proximate the distalmost end face, the device comprising:

- a housing having an inner cavity, wherein an opening to the inner cavity is configured for receiving the access 50 portion of the patient fluid tine access valve;
- a material impregnated with a liquid antimicrobial agent prior to receiving the access portion of the patient fluid line access valve, wherein the material is disposed in the inner cavity; 55
- threading protruding inwardly into the inner cavity from an inner wall of the housing near the opening, the threading configured to engage the external threads of the access portion of the patient fluid line access valve as the housing is placed over the access portion of the 60 patient fluid line access valve to contact the material with the distalmost end face of the access portion of the patient fluid line access valve, and configured to disinfect the distalmost end face and at least a portion of the external threads of the access portion of the patient 65 fluid line access valve with the liquid antimicrobial agent from the material,

wherein the threading receives the external threads of the access portion of the access valve thereby causing the distalmost end face to advance into the inner cavity such that the septum contacts the material.

2. The device of claim 1, wherein a threaded interaction between the threading and the external threads is configured to provide adjustable positioning of the septum within the inner cavity.

3. The device of claim 2, wherein adjustable positioning of the septum within the inner cavity is configured to allow the septum to contact the material, and is further configured to allow the septum to contact and compress the material between the septum and the inner cavity.

4. The device of claim 1, wherein the housing comprises

5. The device of claim 1, wherein the antimicrobial agent comprises at least one of chlorhexidine gluconate and chlorhexidine diacetate.

6. The device of claim 1, wherein the material comprises

7. The device of claim 6, wherein the dry pad comprises a sponge.

8. The device of claim 1, wherein the liquid antimicrobial agent comprises chlorhexidine.

9. The device of claim 1, wherein the liquid antimicrobial agent comprises one or more of the following: chloroxylenol, povidone iodine, Triclosan, and benzethonium chloride.

10. The device of claim 1, wherein the liquid antimicrobial agent comprises one or more of the following: benzalkonium chloride and octenidine.

11. The device of claim 1, wherein the liquid antimicrobial agent comprises an antibiotic.

12. A device for maintaining a patient fluid line access valve having an access portion with a distalmost end face that includes a septum and external threads on the access portion proximate the distalmost end face, the device comprising:

- a housing for covering the access portion of the patient fluid line access valve, the housing having an open end, a closed end, and a cavity, the housing including a thread on an inner wall of the cavity proximate the open end for engaging the external threads on the access portion of the patient fluid line access valve;
- a material impregnated with a liquid antimicrobial agent prior to attachment of the housing to the access portion of the patient fluid line access valve, the material being positioned within the cavity for contacting the distalmost end face of the access portion of the patient fluid line access valve when the housing is positioned over and covers the access portion to reduce the amount of microbes on the access portion,
- wherein in response to insertion of the access portion of the patient fluid line access valve into the cavity, the thread is configured to engage the external threads on the access portion as the access portion is advanced into the inner cavity so that the distalmost end face of the access portion contacts the material to provide the liquid antimicrobial agent to the septum and at least a portion of the external threads.

13. The device of claim 12, wherein the cavity comprises an inner circumference and the thread comprises a length that is less than the inner circumference.

14. The device of claim 12, wherein the antimicrobial agent comprises at least one of chlorhexidine gluconate and chlorhexidine diacetate.

15. A device for maintaining a threaded patient fluid line access valve having an access portion with a distalmost end 5

face that includes a septum and external threads on the access portion proximate the distalmost end face, the device comprising:

- a housing having an inner cavity for covering the access portion of the patient fluid line access valve;
- a material within the housing and impregnated with a liquid antimicrobial agent prior to contacting the patient fluid line access valve, the material being configured to contact at least a portion of the threaded patient fluid line access valve and the distalmost end 10 face of the patient fluid line access valve to reduce the amount of microbes on the patient fluid line access valve;
- a thread within the inner cavity of the housing and positioned between the material and an opening to the 15 inner cavity, the thread for engaging the external threads of the threaded patient fluid line access valve to cause the material to contact the distalmost end face of the patient fluid line access valve,
- wherein in response to the distalmost end face of the 20 access valve being inserted into the housing, the distalmost end face contacts the material to provide the liquid antimicrobial agent to the septum and at least a portion of the external threads.

16. The device of claim **15**, wherein the inner cavity 25 comprises an inner circumference and the thread comprises a length that is less than the inner circumference.

17. The device of claim **15**, wherein the housing comprises a polyethylene or polypropylene material.

18. The device of claim **15**, wherein the liquid antimi- ³⁰ crobial agent comprises at least one of chlorhexidine gluconate and chlorhexidine diacetate.

* * * * *